GSK and Vir Receive the US FDA's EUA for Sotrovimab (VIR-7831) to Treat COVID-19 in Adults and Pediatric Patients
Shots:
- The US FDA has granted EUA for sotrovimab for mild to mod. COVID-19 patients aged ≥12yrs. who are at high risk for progression to severe COVID-19 including hospitalization for >24hrs. or death
- The EUA is based on an interim analysis from the P-III COMET-ICE trial that demonstrated an 85% reduction in hospitalization or death. In vitro data indicate that the therapy maintains activity against all known variants- including Indian variant
- Sotrovimab will be available in the US in the coming wks. and data for the full population from the COMET-ICE trial is expected in H1’21. The companies plan to submit BLA to the FDA in H2’21
Ref: GSK | Image: GSK
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com